|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Sample n°** | ***d*** | ***A*t0** | ***A*t30** | ***A*CXL** | ***β*t0** | ***β*t30** | ***β*CXL** | ***Wt30 (mg)*** | ***WCXL (mg) (α=0)*** |
| **1** | 0.051 | 0.820 | 2.238 | 1.272 | 16.097 | 48.653 | 27.673 | 0.033 | 0.011 |
| **2** | 0.052 | 1.012 | 2.612 | 1.192 | 19.469 |  55.590 | 25.381 | 0.037 | 0.006 |
| **3** | 0.050 | 1.003 | 2.407 | 1.284 | 20.066 | 53.509 | 28.554 | 0.033 | 0.008 |
| **4** | 0.051 | 1.003 | 2.484 | 1.334 | 19.672 | 54.019 | 29.007 | 0.035 | 0.009 |
| **5** | 0.051 | 0.916 | 2.525 | 1.249 | 17.966 | 54.907 | 27.161 | 0.037 | 0.009 |
| **6** | 0.050 | 1.059 | 2.238 | 1.215 | 21.187 | 49.734 | 27.003 | 0.028 | 0.005 |
| **7** | 0.051 | 1.022 | 2.408 | 1.285 | 20.032 | 52.347 | 27.934 | 0.033 | 0.008 |
| **8** | 0.050 | 1.040 | 2.485 | 1.334 | 20.807 | 55.220 | 29.652 | 0.035 | 0.009 |
| **9** | 0.053 | 0.994 | 2.568 | 1.249 | 18.759 | 53.506 | 26.030 | 0.037 | 0.008 |
| **10** | 0.052 | 0.884 | 2.303 | 1.226 | 16.990 | 48.991 | 26.095 | 0.034 | 0.010 |
| **11** | 0.050 | 1.012 | 2.526 | 1.273 | 20.249 | 56.127 | 28.288 | 0.036 | 0.008 |
| **12** | 0.051 | 1.003 | 2.408 | 1.238 | 19.673 | 52.347 | 26.910 | 0.034 | 0.007 |
| **Average** | **0.051** | **0.981** | **2.434** | **1.263** | **19.248** | **52.913** | **27.474** | **0.035** | **0.008** |
| SD | 0.001 | 0.070 | 0.124 | 0.044 | 1.531 |  2.576 |  1.286 | 0.003 | 0.002 |
| p |  |  | **<0.01** | **<0.01** |  | **<0.01** | **<0.01** |  |  |

**Supplemental digital content 2:** Corneal central thickness (d, expressed in cm) and UV-A absorbance values A (dimensionless) and β (cm-1) using an input fluence of 3mW/cm2). The weight of available riboflavin WCXL at the end of the cross-linking treatment has been estimated in the hypothesis that the specific absorbance of the exhaust riboflavin solution is negligible, i.e. α = 0.